Tender Details
Ref No 19523970
Document

Tender Notice

Bidding

Not specified

Short Description

Consultancy To Assess Factors That Affect Adoption Of Biofortified Seeds (Maize And Beans) And Climate Resilient Practices With A View To Accelerating Adoption.
Deadline *
Date 01 Sep 2025
* The estimated cost, values & dates are indicative only. Please read tender document for accurate information.
Client Address
Location Kenya
More Information
Know More

FREE Trial Plan For All New Users!

Start your Business.

Similar Tenders

  • Ref No: 5307616
  • Location: Netherlands

Career Paths Transport And Logistics

  • Deadline: 30 Apr 2026
  • Ref No: 4641405
  • Location: Germany

Medicines With The Active Ingredient Aclidinium Bromide Atc R03Bb05

  • Deadline: 28 Feb 2026
  • Ref No: 5393652
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Fampridine N3

  • Deadline: 10 Nov 2025
  • Ref No: 5837360
  • Location: Germany

Conclusion Of A Non Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For Blood Sugar Test Strips

  • Deadline: 10 May 2026
  • Ref No: 5227070
  • Location: Germany

Medicines With The Active Ingredient Dupilumab Atc D11Ah05

  • Deadline: 31 Mar 2026
  • Ref No: 5229599
  • Location: Germany

Medicines With The Active Ingredient Fampridine Atc N07Xx07

  • Deadline: 31 Mar 2026
  • Ref No: 5965414
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Acarbose Not In Standard Size

  • Deadline: 10 May 2026
  • Ref No: 8267412
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Brinzolamide Brimonidine Atr

  • Deadline: 10 May 2026
  • Ref No: 8294730
  • Location: Germany

Conclusion Of A Non Exclusive Discount Agreement Pursuant To Section 130A Para 8 Sgb V For The Active Ingredient Omalizumab

  • Deadline: 10 Aug 2026
  • Ref No: 8309306
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Pomalidomide

  • Deadline: 10 May 2026
  • Ref No: 8312368
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Bosutinib

  • Deadline: 10 May 2026
  • Ref No: 5716614
  • Location: Germany

Conclusion Of A Non Exclusive Discount Agreement Pursuant To Section 130A Para 8 Sgb V For The Active Ingredient Rituximab

  • Deadline: 11 May 2026
  • Ref No: 5718497
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Tocilizumab

  • Deadline: 11 May 2026
  • Ref No: 5728730
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Bevacizumab

  • Deadline: 10 May 2026
  • Ref No: 5730369
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements In Accordance With Section 130 A Paragraph 8 Sgb V With The Active Ingredient Ranibizumab

  • Deadline: 10 May 2026